The global market for Trivalent Inactivated Influenza Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Trivalent Inactivated Influenza Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Trivalent Inactivated Influenza Vaccine players cover AstraZeneca, Sanofi S.A, Abbott, GlaxoSmithKline and Merck, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Trivalent Inactivated Influenza Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Trivalent Inactivated Influenza Vaccine market, with both quantitative and qualitative data, to help readers understand how the Trivalent Inactivated Influenza Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Doses.
Market Segmentation:
The study segments the Trivalent Inactivated Influenza Vaccine market and forecasts the market size by Type (Nasal Spray, Intramuscular Injection and Intradermal Injection), by Application (Hospital, Clinic, Public Health Agency and Others), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Nasal Spray
Intramuscular Injection
Intradermal Injection
Segmentation by application
Hospital
Clinic
Public Health Agency
Others
Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Major companies covered
AstraZeneca
Sanofi S.A
Abbott
GlaxoSmithKline
Merck
Novartis
Pfizer
Serum Institute of India
CSL Limited
Chapter Introduction
Chapter 1: Scope of Trivalent Inactivated Influenza Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Trivalent Inactivated Influenza Vaccine market size (sales and revenue) and CAGR, Trivalent Inactivated Influenza Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Trivalent Inactivated Influenza Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Trivalent Inactivated Influenza Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Trivalent Inactivated Influenza Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including AstraZeneca, Sanofi S.A, Abbott, GlaxoSmithKline, Merck, Novartis, Pfizer, Serum Institute of India and CSL Limited, etc.
Chapter 14: Research Findings and Conclusion
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Trivalent Inactivated Influenza Vaccine by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Trivalent Inactivated Influenza Vaccine by Country/Region, 2017, 2022 & 2028
2.2 Trivalent Inactivated Influenza Vaccine Segment by Type
2.2.1 Nasal Spray
2.2.2 Intramuscular Injection
2.2.3 Intradermal Injection
2.3 Trivalent Inactivated Influenza Vaccine Sales by Type
2.3.1 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
2.3.2 Global Trivalent Inactivated Influenza Vaccine Revenue and Market Share by Type (2017-2022)
2.3.3 Global Trivalent Inactivated Influenza Vaccine Sale Price by Type (2017-2022)
2.4 Trivalent Inactivated Influenza Vaccine Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Public Health Agency
2.4.4 Others
2.5 Trivalent Inactivated Influenza Vaccine Sales by Application
2.5.1 Global Trivalent Inactivated Influenza Vaccine Sale Market Share by Application (2017-2022)
2.5.2 Global Trivalent Inactivated Influenza Vaccine Revenue and Market Share by Application (2017-2022)
2.5.3 Global Trivalent Inactivated Influenza Vaccine Sale Price by Application (2017-2022)
3 Global Trivalent Inactivated Influenza Vaccine by Company
3.1 Global Trivalent Inactivated Influenza Vaccine Breakdown Data by Company
3.1.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales by Company (2020-2022)
3.1.2 Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Company (2020-2022)
3.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue by Company (2020-2022)
3.2.1 Global Trivalent Inactivated Influenza Vaccine Revenue by Company (2020-2022)
3.2.2 Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Company (2020-2022)
3.3 Global Trivalent Inactivated Influenza Vaccine Sale Price by Company
3.4 Key Manufacturers Trivalent Inactivated Influenza Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Trivalent Inactivated Influenza Vaccine Product Location Distribution
3.4.2 Players Trivalent Inactivated Influenza Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Trivalent Inactivated Influenza Vaccine by Geographic Region
4.1 World Historic Trivalent Inactivated Influenza Vaccine Market Size by Geographic Region (2017-2022)
4.1.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue by Geographic Region
4.2 World Historic Trivalent Inactivated Influenza Vaccine Market Size by Country/Region (2017-2022)
4.2.1 Global Trivalent Inactivated Influenza Vaccine Annual Sales by Country/Region (2017-2022)
4.2.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue by Country/Region
4.3 Americas Trivalent Inactivated Influenza Vaccine Sales Growth
4.4 APAC Trivalent Inactivated Influenza Vaccine Sales Growth
4.5 Europe Trivalent Inactivated Influenza Vaccine Sales Growth
4.6 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Growth
5 Americas
5.1 Americas Trivalent Inactivated Influenza Vaccine Sales by Country
5.1.1 Americas Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022)
5.1.2 Americas Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022)
5.2 Americas Trivalent Inactivated Influenza Vaccine Sales by Type
5.3 Americas Trivalent Inactivated Influenza Vaccine Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Trivalent Inactivated Influenza Vaccine Sales by Region
6.1.1 APAC Trivalent Inactivated Influenza Vaccine Sales by Region (2017-2022)
6.1.2 APAC Trivalent Inactivated Influenza Vaccine Revenue by Region (2017-2022)
6.2 APAC Trivalent Inactivated Influenza Vaccine Sales by Type
6.3 APAC Trivalent Inactivated Influenza Vaccine Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Trivalent Inactivated Influenza Vaccine by Country
7.1.1 Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022)
7.1.2 Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022)
7.2 Europe Trivalent Inactivated Influenza Vaccine Sales by Type
7.3 Europe Trivalent Inactivated Influenza Vaccine Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Trivalent Inactivated Influenza Vaccine by Country
8.1.1 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022)
8.1.2 Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022)
8.2 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Type
8.3 Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Trivalent Inactivated Influenza Vaccine
10.3 Manufacturing Process Analysis of Trivalent Inactivated Influenza Vaccine
10.4 Industry Chain Structure of Trivalent Inactivated Influenza Vaccine
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Trivalent Inactivated Influenza Vaccine Distributors
11.3 Trivalent Inactivated Influenza Vaccine Customer
12 World Forecast Review for Trivalent Inactivated Influenza Vaccine by Geographic Region
12.1 Global Trivalent Inactivated Influenza Vaccine Market Size Forecast by Region
12.1.1 Global Trivalent Inactivated Influenza Vaccine Forecast by Region (2023-2028)
12.1.2 Global Trivalent Inactivated Influenza Vaccine Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Trivalent Inactivated Influenza Vaccine Forecast by Type
12.7 Global Trivalent Inactivated Influenza Vaccine Forecast by Application
13 Key Players Analysis
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Trivalent Inactivated Influenza Vaccine Product Offered
13.1.3 AstraZeneca Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Sanofi S.A
13.2.1 Sanofi S.A Company Information
13.2.2 Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Offered
13.2.3 Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Sanofi S.A Main Business Overview
13.2.5 Sanofi S.A Latest Developments
13.3 Abbott
13.3.1 Abbott Company Information
13.3.2 Abbott Trivalent Inactivated Influenza Vaccine Product Offered
13.3.3 Abbott Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Abbott Main Business Overview
13.3.5 Abbott Latest Developments
13.4 GlaxoSmithKline
13.4.1 GlaxoSmithKline Company Information
13.4.2 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Offered
13.4.3 GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 GlaxoSmithKline Main Business Overview
13.4.5 GlaxoSmithKline Latest Developments
13.5 Merck
13.5.1 Merck Company Information
13.5.2 Merck Trivalent Inactivated Influenza Vaccine Product Offered
13.5.3 Merck Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Merck Main Business Overview
13.5.5 Merck Latest Developments
13.6 Novartis
13.6.1 Novartis Company Information
13.6.2 Novartis Trivalent Inactivated Influenza Vaccine Product Offered
13.6.3 Novartis Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Novartis Main Business Overview
13.6.5 Novartis Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Trivalent Inactivated Influenza Vaccine Product Offered
13.7.3 Pfizer Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Serum Institute of India
13.8.1 Serum Institute of India Company Information
13.8.2 Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Offered
13.8.3 Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 Serum Institute of India Main Business Overview
13.8.5 Serum Institute of India Latest Developments
13.9 CSL Limited
13.9.1 CSL Limited Company Information
13.9.2 CSL Limited Trivalent Inactivated Influenza Vaccine Product Offered
13.9.3 CSL Limited Trivalent Inactivated Influenza Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 CSL Limited Main Business Overview
13.9.5 CSL Limited Latest Developments
14 Research Findings and Conclusion
List of Tables
Table 1. Trivalent Inactivated Influenza Vaccine Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Trivalent Inactivated Influenza Vaccine Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Nasal Spray
Table 4. Major Players of Intramuscular Injection
Table 5. Major Players of Intradermal Injection
Table 6. Global Trivalent Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Doses)
Table 7. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
Table 8. Global Trivalent Inactivated Influenza Vaccine Revenue by Type (2017-2022) & ($ million)
Table 9. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2022)
Table 10. Global Trivalent Inactivated Influenza Vaccine Sale Price by Type (2017-2022) & (US$/Dose)
Table 11. Global Trivalent Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Doses)
Table 12. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2017-2022)
Table 13. Global Trivalent Inactivated Influenza Vaccine Revenue by Application (2017-2022)
Table 14. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2022)
Table 15. Global Trivalent Inactivated Influenza Vaccine Sale Price by Application (2017-2022) & (US$/Dose)
Table 16. Global Trivalent Inactivated Influenza Vaccine Sales by Company (2020-2022) & (K Doses)
Table 17. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Company (2020-2022)
Table 18. Global Trivalent Inactivated Influenza Vaccine Revenue by Company (2020-2022) ($ Millions)
Table 19. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Company (2020-2022)
Table 20. Global Trivalent Inactivated Influenza Vaccine Sale Price by Company (2020-2022) & (US$/Dose)
Table 21. Key Manufacturers Trivalent Inactivated Influenza Vaccine Producing Area Distribution and Sales Area
Table 22. Players Trivalent Inactivated Influenza Vaccine Products Offered
Table 23. Trivalent Inactivated Influenza Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Trivalent Inactivated Influenza Vaccine Sales by Geographic Region (2017-2022) & (K Doses)
Table 27. Global Trivalent Inactivated Influenza Vaccine Sales Market Share Geographic Region (2017-2022)
Table 28. Global Trivalent Inactivated Influenza Vaccine Revenue by Geographic Region (2017-2022) & ($ millions)
Table 29. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Geographic Region (2017-2022)
Table 30. Global Trivalent Inactivated Influenza Vaccine Sales by Country/Region (2017-2022) & (K Doses)
Table 31. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Country/Region (2017-2022)
Table 32. Global Trivalent Inactivated Influenza Vaccine Revenue by Country/Region (2017-2022) & ($ millions)
Table 33. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country/Region (2017-2022)
Table 34. Americas Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022) & (K Doses)
Table 35. Americas Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2017-2022)
Table 36. Americas Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 37. Americas Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2017-2022)
Table 38. Americas Trivalent Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Doses)
Table 39. Americas Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
Table 40. Americas Trivalent Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Doses)
Table 41. Americas Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2017-2022)
Table 42. APAC Trivalent Inactivated Influenza Vaccine Sales by Region (2017-2022) & (K Doses)
Table 43. APAC Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2017-2022)
Table 44. APAC Trivalent Inactivated Influenza Vaccine Revenue by Region (2017-2022) & ($ Millions)
Table 45. APAC Trivalent Inactivated Influenza Vaccine Revenue Market Share by Region (2017-2022)
Table 46. APAC Trivalent Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Doses)
Table 47. APAC Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
Table 48. APAC Trivalent Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Doses)
Table 49. APAC Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2017-2022)
Table 50. Europe Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022) & (K Doses)
Table 51. Europe Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2017-2022)
Table 52. Europe Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 53. Europe Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2017-2022)
Table 54. Europe Trivalent Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Doses)
Table 55. Europe Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
Table 56. Europe Trivalent Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Doses)
Table 57. Europe Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2017-2022)
Table 58. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Country (2017-2022) & (K Doses)
Table 59. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Market Share by Country (2017-2022)
Table 60. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue by Country (2017-2022) & ($ Millions)
Table 61. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country (2017-2022)
Table 62. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Doses)
Table 63. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Market Share by Type (2017-2022)
Table 64. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Doses)
Table 65. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2017-2022)
Table 66. Key Market Drivers & Growth Opportunities of Trivalent Inactivated Influenza Vaccine
Table 67. Key Market Challenges & Risks of Trivalent Inactivated Influenza Vaccine
Table 68. Key Industry Trends of Trivalent Inactivated Influenza Vaccine
Table 69. Trivalent Inactivated Influenza Vaccine Raw Material
Table 70. Key Suppliers of Raw Materials
Table 71. Trivalent Inactivated Influenza Vaccine Distributors List
Table 72. Trivalent Inactivated Influenza Vaccine Customer List
Table 73. Global Trivalent Inactivated Influenza Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 74. Global Trivalent Inactivated Influenza Vaccine Sales Market Forecast by Region
Table 75. Global Trivalent Inactivated Influenza Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 76. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share Forecast by Region (2023-2028)
Table 77. Americas Trivalent Inactivated Influenza Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 78. Americas Trivalent Inactivated Influenza Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 79. APAC Trivalent Inactivated Influenza Vaccine Sales Forecast by Region (2023-2028) & (K Doses)
Table 80. APAC Trivalent Inactivated Influenza Vaccine Revenue Forecast by Region (2023-2028) & ($ millions)
Table 81. Europe Trivalent Inactivated Influenza Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 82. Europe Trivalent Inactivated Influenza Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 83. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Forecast by Country (2023-2028) & (K Doses)
Table 84. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue Forecast by Country (2023-2028) & ($ millions)
Table 85. Global Trivalent Inactivated Influenza Vaccine Sales Forecast by Type (2023-2028) & (K Doses)
Table 86. Global Trivalent Inactivated Influenza Vaccine Sales Market Share Forecast by Type (2023-2028)
Table 87. Global Trivalent Inactivated Influenza Vaccine Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 88. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share Forecast by Type (2023-2028)
Table 89. Global Trivalent Inactivated Influenza Vaccine Sales Forecast by Application (2023-2028) & (K Doses)
Table 90. Global Trivalent Inactivated Influenza Vaccine Sales Market Share Forecast by Application (2023-2028)
Table 91. Global Trivalent Inactivated Influenza Vaccine Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 92. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share Forecast by Application (2023-2028)
Table 93. AstraZeneca Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. AstraZeneca Trivalent Inactivated Influenza Vaccine Product Offered
Table 95. AstraZeneca Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 96. AstraZeneca Main Business
Table 97. AstraZeneca Latest Developments
Table 98. Sanofi S.A Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Sanofi S.A Trivalent Inactivated Influenza Vaccine Product Offered
Table 100. Sanofi S.A Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 101. Sanofi S.A Main Business
Table 102. Sanofi S.A Latest Developments
Table 103. Abbott Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Abbott Trivalent Inactivated Influenza Vaccine Product Offered
Table 105. Abbott Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 106. Abbott Main Business
Table 107. Abbott Latest Developments
Table 108. GlaxoSmithKline Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Product Offered
Table 110. GlaxoSmithKline Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 111. GlaxoSmithKline Main Business
Table 112. GlaxoSmithKline Latest Developments
Table 113. Merck Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Merck Trivalent Inactivated Influenza Vaccine Product Offered
Table 115. Merck Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 116. Merck Main Business
Table 117. Merck Latest Developments
Table 118. Novartis Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Novartis Trivalent Inactivated Influenza Vaccine Product Offered
Table 120. Novartis Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 121. Novartis Main Business
Table 122. Novartis Latest Developments
Table 123. Pfizer Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Pfizer Trivalent Inactivated Influenza Vaccine Product Offered
Table 125. Pfizer Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 126. Pfizer Main Business
Table 127. Pfizer Latest Developments
Table 128. Serum Institute of India Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Serum Institute of India Trivalent Inactivated Influenza Vaccine Product Offered
Table 130. Serum Institute of India Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 131. Serum Institute of India Main Business
Table 132. Serum Institute of India Latest Developments
Table 133. CSL Limited Basic Information, Trivalent Inactivated Influenza Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 134. CSL Limited Trivalent Inactivated Influenza Vaccine Product Offered
Table 135. CSL Limited Trivalent Inactivated Influenza Vaccine Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2020-2022)
Table 136. CSL Limited Main Business
Table 137. CSL Limited Latest Developments
List of Figures
Figure 1. Picture of Trivalent Inactivated Influenza Vaccine
Figure 2. Trivalent Inactivated Influenza Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Trivalent Inactivated Influenza Vaccine Sales Growth Rate 2017-2028 (K Doses)
Figure 7. Global Trivalent Inactivated Influenza Vaccine Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Trivalent Inactivated Influenza Vaccine Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Nasal Spray
Figure 10. Product Picture of Intramuscular Injection
Figure 11. Product Picture of Intradermal Injection
Figure 12. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Type in 2021
Figure 13. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2022)
Figure 14. Trivalent Inactivated Influenza Vaccine Consumed in Hospital
Figure 15. Global Trivalent Inactivated Influenza Vaccine Market: Hospital (2017-2022) & (K Doses)
Figure 16. Trivalent Inactivated Influenza Vaccine Consumed in Clinic
Figure 17. Global Trivalent Inactivated Influenza Vaccine Market: Clinic (2017-2022) & (K Doses)
Figure 18. Trivalent Inactivated Influenza Vaccine Consumed in Public Health Agency
Figure 19. Global Trivalent Inactivated Influenza Vaccine Market: Public Health Agency (2017-2022) & (K Doses)
Figure 20. Trivalent Inactivated Influenza Vaccine Consumed in Others
Figure 21. Global Trivalent Inactivated Influenza Vaccine Market: Others (2017-2022) & (K Doses)
Figure 22. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Application (2017-2022)
Figure 23. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Application in 2021
Figure 24. Trivalent Inactivated Influenza Vaccine Revenue Market by Company in 2021 ($ Million)
Figure 25. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Company in 2021
Figure 26. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Geographic Region (2017-2022)
Figure 27. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Geographic Region in 2021
Figure 28. Global Trivalent Inactivated Influenza Vaccine Sales Market Share by Region (2017-2022)
Figure 29. Global Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country/Region in 2021
Figure 30. Americas Trivalent Inactivated Influenza Vaccine Sales 2017-2022 (K Doses)
Figure 31. Americas Trivalent Inactivated Influenza Vaccine Revenue 2017-2022 ($ Millions)
Figure 32. APAC Trivalent Inactivated Influenza Vaccine Sales 2017-2022 (K Doses)
Figure 33. APAC Trivalent Inactivated Influenza Vaccine Revenue 2017-2022 ($ Millions)
Figure 34. Europe Trivalent Inactivated Influenza Vaccine Sales 2017-2022 (K Doses)
Figure 35. Europe Trivalent Inactivated Influenza Vaccine Revenue 2017-2022 ($ Millions)
Figure 36. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales 2017-2022 (K Doses)
Figure 37. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue 2017-2022 ($ Millions)
Figure 38. Americas Trivalent Inactivated Influenza Vaccine Sales Market Share by Country in 2021
Figure 39. Americas Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country in 2021
Figure 40. United States Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 41. Canada Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 42. Mexico Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 43. Brazil Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 44. APAC Trivalent Inactivated Influenza Vaccine Sales Market Share by Region in 2021
Figure 45. APAC Trivalent Inactivated Influenza Vaccine Revenue Market Share by Regions in 2021
Figure 46. China Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 47. Japan Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 48. South Korea Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 49. Southeast Asia Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 50. India Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 51. Australia Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 52. Europe Trivalent Inactivated Influenza Vaccine Sales Market Share by Country in 2021
Figure 53. Europe Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country in 2021
Figure 54. Germany Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 55. France Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 56. UK Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 57. Italy Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 58. Russia Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 59. Middle East & Africa Trivalent Inactivated Influenza Vaccine Sales Market Share by Country in 2021
Figure 60. Middle East & Africa Trivalent Inactivated Influenza Vaccine Revenue Market Share by Country in 2021
Figure 61. Egypt Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 62. South Africa Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 63. Israel Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 64. Turkey Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 65. GCC Country Trivalent Inactivated Influenza Vaccine Revenue Growth 2017-2022 ($ Millions)
Figure 66. Manufacturing Cost Structure Analysis of Trivalent Inactivated Influenza Vaccine in 2021
Figure 67. Manufacturing Process Analysis of Trivalent Inactivated Influenza Vaccine
Figure 68. Industry Chain Structure of Trivalent Inactivated Influenza Vaccine
Figure 69. Channels of Distribution
Figure 70. Distributors Profiles
Global Freckle-removing Medical and Beau..
The global market for Freckle-removing Medical and Beauty Eq..
+16467917070US (Toll Free)